Pharmaceuticals News and Research

RSS

Haemacure announces closing of purchase by Angiotech Pharmaceuticals

Haemacure Corporation announces the closing of the purchase by Angiotech Pharmaceuticals, Inc. of substantially all its assets, consisting mainly of its two product candidates and the associated intellectual property and manufacturing plant.

8 Apr 2010

Atlantic-Pacific Capital raises $701M through DRI Capital managed Drug Royalty II fund

Atlantic-Pacific Capital, a leading independent global placement agent, announced today the final closing of Drug Royalty II with $701 million of equity capital commitments. The Fund, managed by DRI Capital, had an initial target of $500 million and received tremendous support from a broad group of institutional investors across the U.S., Canada, Europe, Australia and Asia. Atlantic-Pacific Capital acted as the exclusive global placement agent and advisor.

8 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution (with Flavor Packs), the generic version of Braintree Laboratories' NuLytely® laxative.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18

Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.

8 Apr 2010

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

8 Apr 2010

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

8 Apr 2010

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

Valeant Pharmaceuticals International prices $400M of 7.625% senior unsecured notes due 2020

Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.

7 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

BeaconEquity.com releases investment report on Cell Therapeutics

BeaconEquity.com announces an investment report featuring biotech company Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

7 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Raptor Pharmaceutical Corp., today announced the engagement of The Trout Group LLC, a leading New York-based investor relations and strategic advisory firm. The Trout Group will work with Raptor to facilitate the Company's exposure to the international capital markets and coordinate their communications with investors worldwide.

7 Apr 2010

Health care reform: Clarification for seniors

From the time presidential candidate Theodore Roosevelt first discussed health care reform in 1912, the topic has been a precedent-setting issue in the U.S. The 2010 passage of health care legislation is no different, but has many Americans in a quandary about how it will affect them. This is especially true of senior citizens.

7 Apr 2010

Updated report analyzing approval rates at FDA published

Sagient Research Systems, a leading publisher of independent research for the financial services, institutional investment and corporate intelligence communities, recently published an updated report analyzing approval rates at the U.S Food and Drug Administration. According to its research service, BioMedTracker, the rate of drugs that were approved by the FDA in 2008 and 2009 has remained close to the historical low seen in 2007.

7 Apr 2010

Investment report featuring Antares Pharma from BeaconEquity.com

BeaconEquity.com announces an investment report featuring medical instruments company Antares Pharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

Brazil healthcare market to reach $129.9 billion in 2012

On the road to global economic recovery, the BRIC countries (Brazil, Russia, India and China) are setting up a new scene. Brazil, in particular, is the 9th economy in the world and is expected to reach the 8th position by 2012. New opportunities set a promising healthcare market perspective with a strong potential for further growth.

7 Apr 2010

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

7 Apr 2010

Pharmaceuticals News and Research

Haemacure announces closing of purchase by Angiotech Pharmaceuticals

Atlantic-Pacific Capital raises $701M through DRI Capital managed Drug Royalty II fund

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

FDA approves Mylan Pharmaceuticals' generic NuLytely laxative

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

Avid Radiopharmaceuticals, PETNET Solutions collaborate in manufacture of Florbetapir F 18

USFDA approves Sun Pharmaceutical Industries' ANDA for generic Wellbutrin SR Extended Release tablets

FDA grants final approval for Teva Pharmaceutical Industries' generic Hyzaar and Cozaar

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

Valeant Pharmaceuticals International prices $400M of 7.625% senior unsecured notes due 2020

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

BeaconEquity.com releases investment report on Cell Therapeutics

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Health care reform: Clarification for seniors

Updated report analyzing approval rates at FDA published

Investment report featuring Antares Pharma from BeaconEquity.com

Brazil healthcare market to reach $129.9 billion in 2012

StockPreacher.com: GenVec's revenues for 2009 decline by 8%

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence